Background. The nutritional and body shape response after the initiation of highly active antiretroviral therapy (HAART) in resource-limited environments has not been documented. In this environment, nutritional compromise is a common complication of human immunodeficiency virus (HIV) infection.
. Patients were stratified into those who lost weight (loss of 11 kg, 22%;
), those whose weight remained stable (19%; ), and those who gained weight (gain n p 41 n p 37 of 11 kg, 59%;
). Patients in all groups retained body shape symmetry and experienced no change in n p 112 waist-to-hip ratio or regional body shape by anthropometry.
Conclusions. The group that lost weight and the group whose weight remained stable experienced significant CD4 + T cell count increases at 6 months. Although the majority of HIV-infected patients who received nevirapinebased HAART gained weight, there were participants who lost weight despite initiating their first HAART therapy.
There are 15.1 million HIV-infected individuals in India [1] . Many of the patients in South India with HIV infection already have advanced disease and are eligible for HAART [2] . Dramatic reductions in HIV-related morbidity and mortality have been observed in HIV-infected patients who have had access to HAART [3] . Because of decreasing costs of antiretroviral drugs and production by generic manufacturers, tertiary care centers in resource-limited environments are now able to provide antiretroviral therapy to HIV-infected patients who meet the criteria for treatment [4] . As expected, this has led to reduced morbidity and mortality associated with HIVrelated opportunistic infections in India [2] .
HIV-associated wasting has been an extremely common complication of untreated HIV infection and has been associated with significant morbidity and mortality [5, 6] . HIV-associated weight loss in HAARTtreated individuals has been less severe than in untreated individuals. This is presumed to be caused by the suppression of viral replication in HIV-infected individuals, which is thought to lead to improvements in patients' weights and body mass indices (BMIs; calculated as weight in kilograms divided by the square of height in meters); however, there are limited prospective data to support this presumption [7] . In addition, alterations in body shape (e.g., central fat depo- sition and subcutaneous fat atrophy) have been noted in HIVinfected patients, particularly those who are receiving HAART, but the role of therapy has not been clear in the development of these changes [8] [9] [10] .
We present prospective data on the impact of a nevirapine (NVP)-based HAART regimen on the weight, BMI, and body composition of treatment-naive, HIV-infected patients in South India. Longitudinal, objective data on the nutritional response to or the occurrence of body shape changes in an HIV-infected, antiretroviral therapy-naive population who are initiating NVPbased HAART in South India are, to our knowledge, not otherwise available.
METHODS
We conducted a prospective cohort study at the YR Gaitonde Center for AIDS Research and Education in Chennai, South India, one of the largest organizations to provide a continuum of care to HIV-infected patients since 1993. The first 190 HIVpositive, antiretroviral therapy-naive adult patients who were initiating NVP-based HAART at our center were included in the study; in the current analysis, they were observed prior to initiation of HAART and after the initial 6 months of therapy.
Study methods. Anthropometry and bioelectrical impedance analysis (BIA) was used to assess nutritional status in this study. All anthropometric measures were made by a single trained observer (S.S.) to minimize variation. Weight was obtained to the nearest 0.1 kg using a standardized scale, with the patient wearing minimal clothing and without shoes or heavy objects. Height was measured to the nearest millimeter using a stadiometer, without shoes, with the participant's heels, buttocks, and shoulder blades in contact with the wall. Skin fold measurements were obtained in triplicate at the triceps, suprailiac, and subscapular sites using Harpenden's calipers. Midarm circumference was measured on the upper right arm with a nonelastic flexible tape. Waist circumference around the narrowest part of the waist and hip circumference around the broadest part of the hip or buttocks were obtained, with the subject standing relaxed, with feet together and arms at the sides. The waist-to-hip ratio was calculated from these measures [11] . BIA was performed using a handheld analyzer (Quantum II; RJL Systems) and calculated with Cyprus Body Composition Analysis software, version 1.2 (RJL Systems). CD4 + T cell counts were analyzed using flow cytometry and were quality assured by Johns Hopkins University (Baltimore, MD). Viral loads were not available for this population.
Definitions. At the 6-month follow-up visit, patients were defined as being in (1) the weight loss group, if a decrease in weight of 11 kg was observed; (2) the weight stable group, if an increase or decrease in weight of р1 kg was observed; or (3) the weight gain group, if an increase in weight of 11 kg was observed.
Study population. A patient was enrolled in the study when the CD4 + T cell count decreased to !250 cells/mm 3 after NVPbased HAART was initiated; if, upon entry to clinical care, the CD4 + T cell count was !200 cells/mm 3 ; or if the patient was symptomatic or presented to a health care provider with an opportunistic illness, regardless of CD4 + T cell count. Patients who received a diagnosis of HIV infection and had tuberculosis, were successfully receiving treatment for tuberculosis, and subsequently initiated HAART were eligible for the study. Therapy was initiated using fixed drug combinations of zidovudine 200 mg twice daily, lamivudine 150 mg twice daily, and nevirapine 200 mg twice daily (after a 2-week run-in period of nevirapine 200 mg once daily), unless the hemoglobin level was !9 mg/ dL, in which case zidovudine was replaced with stavudine at 30-40 mg twice daily, depending on body weight. All therapeutic agents were generic and were obtained from CIPLA Pharmaceuticals (Mumbai, Maharashtra, India).
Statistical analysis. One-way analysis of variance was performed to compare the significance between weight change groups over the 6-month period. A paired Student's t test was performed to compare the significance within each weight change group over the 6-month period. An independent Student's t test was performed to compare the change between the zidovudine and stavudine groups that was observed at 6 months after initiation of HAART. Statistical analyses were performed with SPSS software, version 10.05 (SPSS). Table 1 outlines the basic characteristics of the cohort that was enrolled in this study. Weight and body composition measurements were recorded at baseline (prior to initiation of therapy) and at 6 months after initiation of therapy for 190 subjects (mean age, 35 years [range, 20-62 years]; 85% were male) who NOTE. BCM, body cell mass; BMI, body mass index (calculated as weight in kilograms divided by the square of height in meters); MAC, midarm circumference; SISF, suprailiac site skin fold measurement; SSF, subscapular site skin fold measurement; TSF, triceps site skin fold measurement; W/H, waist-to-hip ratio.
RESULTS
a Measurement determined using bioelectrical impedance analysis.
initiated HAART. Stavudine was included in 59.5% of the starting regimens. Table 2 describes the nutritional and body shape parameters of the 190 subjects at baseline and after 6 months. Overall, the cohort had a mean BMI of 20.1 before the initiation of therapy. Body weight increased significantly (mean increase ‫ע‬ SD, kg; range, Ϫ12.5 to 22.5 kg) in a majority of subjects. 2.8 ‫ע‬ 5.4 With the exception of waist-to-hip ratio, the mean value of all other body shape parameters also increased in the treatment cohort. Although viral load data were not available at baseline or follow-up, the overall cohort experienced a mean CD4 + T cell increase of 140 cells/mm 3 , suggesting an appropriate response to HAART.
The range of change in weight was so broad that patients were stratified into 3 groups for further analysis: those who lost weight (weight loss defined as 11 kg) at 6 months, those who remained weight stable (those participants who experienced a weight change р1 kg) at 6 months, and those who gained weight (11 kg) at 6 months. Forty-one (22%) of the patients lost weight, a mean decrease of 3.6 kg from baseline, with a mean baseline BMI of 21.4. BMI was significantly higher at baseline ( ) in the weight loss group. BMI and body P ! .001 composition (body fat and body cell mass measured by BIA) changed symmetrically in all 3 groups; that is, patients who gained weight gained both fat and body cell mass (table 3) . Patients who remained weight stable had no change in fat or body cell mass, and patients who lost weight lost both fat and body cell mass. Waist-to-hip ratio did not change, again suggesting that changes were symmetrical and not caused by fat redistribution. Among the 41 patients who lost weight, 5 patients (12%) experienced a weight loss of 110% of their baseline weight. The weight loss group had an initial body fat percentage of 14%, which decreased to 12% at 6 months. A significant increase in CD4 + T cell count was observed at 6 months in the weight loss group.
Thirty-seven patients in the cohort (19%) remained weight stable, with a baseline BMI of 20.2. Changes from baseline to 6 months for the weight stable group are shown in table 3. Although a significant increase in CD4 + T cell count at 6 months was observed, no changes were observed in this group in weight, BMI, body shape, or body composition. Body fat (measured by BIA) in this group began and remained at 14%.
One hundred twelve patients (59%) gained a mean of 6 kg (from a mean baseline BMI of 19.6). In the weight gain group (table 3) , all parameters except waist-to-hip ratio increased significantly. Mean body fat percentage by BIA at baseline in this group was 11.9%, which increased at 6 months to 16%. This group also experienced a significant increase in CD4 + T cell count. Mean BMI at 6 months in all 3 groups was 20.1-21.7.
Mean ages ‫ע(‬ SDs) for the weight loss, weight stable, and weight gain groups were years, years, and 36.4 ‫ע‬ 6.4 34.7 ‫ע‬ 5.5 years, respectively; the difference that was observed 35.0 ‫ע‬ 6.8 was not statistically significant, although the weight loss group had a slightly higher mean age. According to the 2003 edition of the WHO staging system for HIV infection and disease in adults and adolescents [12] , the weight loss, weight stable, and weight gain groups comprised 90%, 92%, and 92% of patients, respectively, who were classified as being in clinical stage IV at the time of study entry and therapy initiation. No difference was observed in the number of subjects with a nadir CD4 + T cell count !100 cells/mm 3 at any point in the weight loss, weight stable, and weight gain groups (46%, 38%, and 47%, respectively). The mean duration of known HIV infection (time since the first positive HIV test result) was 1.4, 1.5, and 0.9 years in the weight loss, weight stable, and weight gain groups, respectively. There was no difference in the percentages of patients in the 3 groups who were being treated for tuberculosis: 24.4% in the weight loss group, 32.4% in the weight stable group, and 19.6% in the weight gain group. There was also no significant difference among the 3 groups in the percentage of patients who were receiving stavudine (39%, 48.6%, and 68.8% for the weight loss, weight stable, and weight gain groups, respectively). Because of the concern that stavudine use might result in a predisposition to subcutaneous fat atrophy, the cohort was also stratified by stavudine use in the initial HAART regimen. Table  4 shows the differences in weight, BMI, circumference measurements, and body composition between baseline and 6-month follow-up when the group was stratified by use of stavudine or zidovudine in the initial treatment regimen.
DISCUSSION
HIV disease was relatively advanced in this cohort (mean baseline CD4 + T cell count, 175 cells/mm 3 ), because the requirement for initiation of HAART was a CD4 + T cell count !200 cells/ mm 3 . Mean BMI in the cohort was 20.1, which was in the normal range (18.5-25.0) but was lower than the national average of 23.3, as observed in the year 2000 by the National Urban Diabetes Survey in India [13] . The percentage of patients who had a BMI !18.5 was 33.7% in this cohort, whereas it was 48% in India as a whole (as observed by the National Nutrition Monitoring Board survey, 1996-1997). Cross-sectional data from our center reveal that body weight was significantly lower among HIV-infected subjects (mean BMI, 19.4;
), comn p 100 pared with HIV-negative control subjects (mean BMI, 21.4;
). This suggests that weight differences among HIVn p 50 infected patients and HIV-negative control subjects in India parallel those differences observed in resource-sufficient environments [14] .
Carbonnel et al. [15] observed that body weight changes correlated strongly with changes in CD4 + T cell count as a result of treatment with the protease inhibitor indinavir. Mwamburi et al. [7] observed that weight changed in association with changes in viral load in untreated, HIV-infected patients and in association with changes in CD4 + T cell count in patients who received HAART. In the current study, body weight changes did not correspond to the degree of CD4 + T cell reconstitution that resulted from treatment. In our population, baseline CD4 + T cell count, a nadir CD4 + T cell count !100 cells/mm 3 at any time during a patient's illness, and CD4 + T cell count response to initiation of HAART were not different among the 3 groups and did not appear to predict weight gain or weight loss. What was particularly striking in our cohort was the range in change in weight after 6 months of NVP-based HAART. To examine this more closely, we stratified our patients by nutritional response (weight loss, weight stable, weight gain) as well as by the use of stavudine. Nearly 60% of the cohort gained weight as a result of improvement in nutritional status after initiation of HAART. It is interesting to note that, despite successful HAART (measured using CD4 + T cell count as a surrogate marker of response to therapy), 22% of the cohort lost weight, although they had a higher baseline BMI. The group that remained weight stable remained remarkably stable, with no significant change in any body shape or body composition parameters. Further follow-up for 11 year will shed more light on body shape changes, so that differences between weight loss and fat atrophy in this population may be better understood.
Because of the high prevalence of anemia, a large percentage of patients in this study received stavudine, which has been associated with fat atrophy, as a part of HAART. However, these patients experienced a robust and symmetrical increase in all body shape parameters (including subcutaneous fat measurements by triceps skin fold and hip circumference), compared with the individuals in our study who initiated therapy with zidovudine.
A recent cross-sectional study [16] suggested that patients in Pune, India, who were treated with NVP-based HAART had frequent and subjective recognition of body shape alteration, including fat atrophy and fat deposition. However, in this study, there were no objective measures of body shape and no longitudinal follow-up of patients. Weight loss or nutritional compromise in HIV-infected patients is often thought to be associated with inadequate food intake, malabsorption of nutrients, opportunistic infections or malignancies, diarrhea, or hormonal (e.g., testosterone) deficiencies [17] . We do not currently have data that can explain the differences in the nutritional responses in this cohort to the introduction of NVP-based HAART or why the group of patients who lost weight did so. Also, it is not possible to distinguish between weight loss and fat atrophy. Therefore, it will be important to monitor HIV-infected patients in South India who are receiving HAART over a more prolonged period of time to determine the ultimate pattern of weight gain and loss and how it is related to the response to specific HAART regimens. It will also be important to determine if metabolic and body-shape abnormalities become common in this HIVinfected population as duration of patient survival increases with the use of HAART.
LIMITATIONS OF THE STUDY
This is an initial, objective observation of the nutritional response to NVP-based HAART. Long-term follow-up is essential to clearly describe the HAART-associated body shape changes experienced by this population. Data on the adequacy of dietary intake and change in viral load, as well as other reasons for weight loss in these patients, would be important parameters to know, but they are not available in this study.
